You are here: Industry Insights > Evenity

News List

EC approves treatment for severe osteoporosis postmenopausal women europeanpharmaceuticalreview
December 16, 2019
Marketing authorisation has been granted by the EC for Evenity® (romosozumab) to treat osteoporosis in postmenopausal women.
Amgen-UCB’s Evenity receives EC approval to treat osteoporosis pharmaceutical-technology
December 16, 2019
Amgen and UCB have received the European Commission (EC) approval for Evenity (romosozumab) to treat severe osteoporosis in postmenopausal women at high fracture risk.
FDA Approves Evenity (romosozumab-aqqg) for the Treatment of Osteoporosis in Postmenopausal Women at High Risk of Fracture drugs
April 11, 2019
FDA Approves Evenity (romosozumab-aqqg) for the Treatment of Osteoporosis in Postmenopausal Women at High Risk of Fracture.
FDA approves Amgen, UCB's postmenopausal osteoporosis drug Evenity firstwordpharma
April 10, 2019
The FDA announced Tuesday that it approved Amgen and partner UCB's Evenity (romosozumab-aqqg) to treat osteoporosis in postmenopausal women at high risk of fracture.
FDA Approves Evenity drugs
April 10, 2019
FDA Approves Evenity (romosozumab-aqqg) for the Treatment of Osteoporosis in Postmenopausal Women at High Risk of Fracture
FDA asks for additional data to approve Evenity in US pharmaceutical-technology
July 19, 2017
Pharmaceutical companies Amgen and UCB have received a Complete Response Letter from the US Food and Drug Administration (FDA) for Evenity, a treatment for postmenopausal women with osteoporosis.